PT-141 — Peptide Dosing Protocols reference
patient_educationexpert_opinion · status: needs_provider_reviewDetails
Summary (generated — provider review required)
PT-141 (bremelanotide) Dosage Guide: Timing, Protocol & Side Effects (2026) Shop Protocols Stacks A–Z Index Email Updates Home Protocols PT-141 (Bremelanotide) Dosage Guide: Timing, Protocol & Side Effects Protocol / Research Dosing Guide PT-141 (Bremelanotide) Dosage Guide: Timing, Protocol & Side Effects An evidence-based PT-141 protocol guide covering dosing structure, timing, reconstitution math, route considerations, and side effects for this bremelanotide peptide. By Garret Grant · Founder & Lead Researcher · Last reviewed June 2026 · Share Supplier Pick Copy code PEPPAL Copy code PEPPAL Verified Supplier Verified Supplier Peptide Partners PT-141 Supply View supply Table of Contents View Supplies Quick Start Dosing Protocol & Schedule Supplies Needed Reconstitution Guide Mechanism Who Should Avoid It Side Effects & Safety Timeline & Monitoring Clinical Evidence Storage & Handling Troubleshooting Regulatory Status PT-141 Comparisons Related Protocols Blood Tests FAQ References PT-141 Quick Start PT-141 (also called bremelanotide, peptide 141, or pt141) is a synthetic cyclic peptide that activates two melanocortin receptors in the brain, MC3R and MC4R. It is the active ingredient in Vyleesi , an FDA-approved injection for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD).
The original source document remains the source of truth. Generated summaries are not authoritative.
Linked assets (8) · phenotypes (0)
evidence_reference, dosing_reference, mechanism, safety_reference, contraindication_reference, monitoring_reference
Findings (173) · awaiting review (132)
safety · pending
Optional Monitoring guidance is label-informed for cardiovascular and reproductive cautions, with optional hormone labs based on clinical context.
dosing · pending
Receptor downregulation has been raised as a theoretical concern with very frequent melanocortin agonist exposure, which is part of why the Vyleesi label caps monthly use at 8 doses.
dosing · pending
By Garret Grant · Founder & Lead Researcher · Last reviewed June 2026 · Share Supplier Pick Copy code PEPPAL Copy code PEPPAL Verified Supplier Verified Supplier Peptide Partners PT-141 Supply View supply Table of Contents View Supplies Quick Start Dosing Protocol & Schedule Supplies Needed Reconstitution Guide Mechanism Who Should Avoid It Side Effects & Safety Timeline & Monitoring Clinical Evidence Storage & Handling Troubleshooting Regulatory Status PT-141 Comparisons Related Protocols Blood Tests FAQ References PT-141 Quick Start PT-141 (also called bremelanotide, peptide 141, or pt141) is a synthetic cyclic peptide that activates two melanocortin receptors in the brain, MC3R and MC4R.
regulatory · pending
It is the active ingredient in Vyleesi , an FDA-approved injection for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD).
dosing · pending
The dosing information here describes the FDA-approved Vyleesi label and published clinical trial protocols.
dosing · pending
Approved route Subcutaneous injection (Vyleesi autoinjector).
dosing · pending
Approved dose 1.75 mg subcutaneous, ≥45 minutes before sexual activity, per the Vyleesi label.
dosing · pending
Approved frequency No more than one dose per 24 hours; no more than 8 doses per month.
regulatory · pending
Approved population Premenopausal women with acquired, generalized HSDD.
regulatory · pending
Not approved for postmenopausal women, men, or pediatric use.
mechanism · pending
Research status Mechanism well characterized.
regulatory · pending
PT-141 used outside the FDA-approved Vyleesi indication is off-label and not supported by Phase 3 evidence in those populations.
dosing · pending
PT-141 Dosing Protocol & Schedule PT-141 is studied in two main administration formats: the FDA-approved subcutaneous injection (Vyleesi) and an investigational intranasal route used in earlier Phase 2 work.
dosing · pending
Dosing is meaningfully different between the two routes because of how each is absorbed.
regulatory · pending
Intranasal (Investigational) FDA-approved injectable route for premenopausal women with HSDD.
dosing · pending
The FDA-approved label for Vyleesi (bremelanotide injection) lists 1.75 mg subcutaneous at least 45 minutes before anticipated sexual activity, no more than one dose in any 24-hour period, and no more than 8 doses per month.
dosing · pending
This is not a dosing recommendation.
dosing · pending
In the Phase 3 RECONNECT trials (Kingsberg 2019), about 1,200 premenopausal women self-administered 1.75 mg subcutaneous bremelanotide or placebo using an autoinjector, on demand, for 24 weeks.
outcome · pending
Both trials met their co-primary endpoints of improved sexual desire and reduced distress related to low desire.
dosing · pending
The 1.75 mg flat dose was used regardless of body weight.
dosing · pending
The 1.75 mg dose was used regardless of body weight.
dosing · pending
Vyleesi Label Protocol (FDA-approved) Parameter Dose Value 1.75 mg Source Vyleesi label / Mayo Clinic drug summary Parameter Route Value Subcutaneous (abdomen or thigh) Source Vyleesi label Parameter Timing Value ≥45 minutes before sexual activity Source Vyleesi label Parameter Maximum frequency Value 1 dose per 24 hours Source Vyleesi label Parameter Maximum monthly use Value 8 doses per month Source Vyleesi label Parameter Approved population Value Premenopausal women with HSDD Source Vyleesi label Parameter Value Source Dose 1.75 mg Vyleesi label / Mayo Clinic drug summary Rou
dosing · pending
te Subcutaneous (abdomen or thigh) Vyleesi label Timing ≥45 minutes before sexual activity Vyleesi label Maximum frequency 1 dose per 24 hours Vyleesi label Maximum monthly use 8 doses per month Vyleesi label Approved population Premenopausal women with HSDD Vyleesi label Reflects the FDA-approved Vyleesi label as summarized by Mayo Clinic (last updated Feb 2026).
dosing · pending
This is not a personal dosing recommendation.
regulatory · pending
Compounded nasal sprays used off-label; based on early Phase 2 research, not Phase 3-approved.
dosing · pending
The published intranasal arms studied 7.5 mg, 15 mg, and 20 mg doses, with pro-erectile effects observed.
regulatory · pending
Pharmaceutical development later moved to the injectable route for the female HSDD indication, and intranasal PT-141 was never advanced to Phase 3 or FDA approval .
dosing · pending
This is not a dosing recommendation.
dosing · pending
Compounded nasal sprays sold through some men's clinics use lower per-actuation amounts than the original Phase 2 doses.
dosing · pending
These products are not FDA-approved formulations, dosing varies by compounding pharmacy, and per-spray delivery depends on the specific metered device.
dosing · pending
The community-used range frequently cited is 1-2 mg per actuation, but the actual delivered amount depends on the compounded concentration and device.
regulatory · pending
Evidence boundary Intranasal PT-141 is not FDA-approved.
dosing · pending
The strongest published human evidence is a Phase 2 trial in men with ED at higher per-dose amounts than typical compounded sprays.
dosing · pending
Cycle Guidelines PT-141 use patterns reported in the literature and FDA label Approach FDA-approved on-demand (Vyleesi) Pattern 1.75 mg subQ ≥45 min before activity, ≤1/24h, ≤8/month Reference Source Vyleesi label (Mayo Clinic summary) Approach Phase 3 trial schedule Pattern 1.75 mg subQ on demand for 24 weeks Reference Source Kingsberg 2019 (RECONNECT) Approach Long-term safety extension Pattern 1.75 mg subQ on demand for an additional 52 weeks Reference Source Simon 2019 (open-label extension) Approach Phase 2 intranasal (men with ED) Pattern 7.5-20 mg intranasal in trial arms studied Reference Source Diamond 2006 Approach Pattern Reference Source FDA-approved on-demand (Vyleesi) 1.75 mg subQ ≥45 min before activity, ≤1/24h, ≤8/month Vyleesi label (Mayo Clinic summary) Phase 3 trial schedule 1.75 mg subQ on demand for 24 weeks Kingsberg 2019 (RECONNECT) Long-term safety extension 1.75 mg subQ on demand for an additional 52 weeks Simon 2019 (open-label extension) Phase 2 intranasal (men with ED) 7.5-20 mg intranasal in trial arms studied Diamond 2006 Frequency recommendations refle
regulatory · pending
ct trial protocols and the FDA-approved label, not personal use guidance.
dosing · pending
The label does not advise weight-based dose adjustment.
safety · pending
Long-term safety beyond the 76 weeks studied in Kingsberg 2019 and Simon 2019 has not been formally established.
dosing · pending
Boundary Peptide Dosing Protocols does not publish personalized dosing recommendations.
regulatory · pending
Information here reflects the FDA-approved label and published clinical trials.
dosing · pending
PT-141 Supplies Needed Supply estimates below assume a 10 mg research vial reconstituted with 2 mL of bacteriostatic water (5 mg/mL), a 1.75 mg per-dose plan (the FDA-approved Vyleesi dose), and the maximum 8 doses per month allowed under the Vyleesi label.
Processing
Processed into 26 searchable sections.